Amneal Pharmaceuticals, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Amneal reported Q2 2026 net revenue of $796 million (up 10% from $725M in Q2 2025) with GAAP net income of $58 million and adjusted EBITDA of $206 million. The company raised full-year 2026 guidance: net revenue to $3.10–$3.20B (from $3.05–$3.15B), adjusted EBITDA to $750–$780M (from $740–$770M), and adjusted diluted EPS to $0.96–$1.06 (from $0.95–$1.05). In July 2026, Amneal repriced $2.084B in Term Loan B debt, reducing the interest rate by 50 basis points (SOFR+300bps to SOFR+250bps), generating ~$12M annual interest savings; the company also plans to borrow an additional $350M Term Loan B to partially fund the pending acquisition of Kashiv Biosciences, a biosimilars business.
Why this rating
Revenue growth modest (+10%); guidance raises incremental. Kashiv acquisition strategic but unfinalized. Debt repricing saves ~$12M annually (0.7% of $1.7B market cap)—routine. Leverage 3.6x net—elevated but stable.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.